Thursday 22 October 2026
Export XNCR’s income statement to Excel — free account
Xencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024. In the quarter to June 2026, revenue grew 17.5%, EPS grew 29.3% and free cash flow fell 52.9%, each against the same quarter a year earlier.
25.90
0.74
+2.94%
Follow XNCR
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
23.02 | 0.00 | 0.00 | 70.18 | 0.00 | 28.25 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
6 | 3 | 2 | 6 | 1 | 4 | 3 | 1 | 2 | 3 |
P/S ratio |
9.51 | 14.41 | 23.43 | 12.41 | 20.34 | 8.51 | 9.41 | 7.80 | 13.53 | 9.05 |
Altman Z-Score |
5.60 | 7.68 | 20.64 | 15.70 | 11.42 | 13.96 | 8.03 | 2.29 | 2.31 | 1.73 |
Altman Z″-Score (non-manufacturers) |
2.30 | 4.31 | 10.18 | 11.59 | 6.99 | 9.37 | 9.21 | 3.60 | 2.25 | 2.23 |
P/FCF ratio |
11.24 | 0.00 | 0.00 | 36.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(68.37) | (160.13) | (116.24) | (99.31) | 146.11 | 37.91 | (63.36) | 74.96 | (29.99) | (21.98) |
Beneish M-Score |
44.71 | (4.11) | 6.88 | 0.97 | (4.06) | 3.37 | (3.93) | (2.73) | (0.18) | (2.86) |
P/B ratio |
3.30 | 3.37 | 3.74 | 3.28 | 4.36 | 3.19 | 2.13 | 2.06 | 2.22 | 1.79 |
Price to Tangible BV |
3.42 | 3.50 | 3.83 | 3.36 | 4.49 | 3.27 | 2.18 | 2.12 | 2.28 | 1.81 |
EV/Sales |
8.32 | 11.38 | 19.89 | 9.09 | 15.53 | 7.42 | 5.98 | 5.48 | 10.50 | 5.64 |
EV/EBITDA |
18.93 | 0.00 | 0.00 | 101.63 | 0.00 | 36.89 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
9.52 | (25.10) | (20.77) | 22.14 | (380.66) | (121.18) | 40.21 | (12.29) | (5.74) | (5.24) |
EV/FCF |
9.83 | (20.63) | (18.63) | 26.72 | (101.48) | (62.23) | (52.04) | (9.66) | (5.48) | (5.09) |
Quick Ratio |
1.31 | 3.10 | 5.67 | 8.29 | 5.08 | 5.66 | 10.21 | 8.35 | 6.39 | 6.02 |
Current Ratio |
1.33 | 3.18 | 5.86 | 8.39 | 5.27 | 6.00 | 10.58 | 8.60 | 6.61 | 6.25 |
Net Debt/EBITDA |
(2.72) | 5.92 | 3.86 | (37.02) | 8.36 | (5.42) | 7.82 | 3.03 | 1.86 | 2.51 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.60% | 1.65% | 4.05% | 7.05% | 19.63% | 17.19% | 13.68% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.05 | 0.08 | 0.29 | 0.24 | 0.19 |
Asset Turnover |
0.34 | 0.11 | 0.08 | 0.25 | 0.18 | 0.36 | 0.20 | 0.19 | 0.12 | 0.14 |
Operating CF/Net income |
2.11 | 0.87 | 1.13 | 2.40 | 0.07 | (0.20) | (0.44) | 0.59 | 0.87 | 1.47 |
Capex/Depreciation |
(0.78) | (1.38) | (2.95) | (55.75) | (2.27) | (1.38) | (4.16) | 24.43 | 5.92 | (0.45) |
Interest Coverage |
2,097.14 | (10.28) | (8.72) | 1.02 | (10.57) | 3,366.69 | (6,344.08) | (21.43) | (4.87) | (5.56) |
| 18.94% | (12.21%) | (16.80%) | 4.82% | (11.90%) | 12.65% | (7.55%) | (19.16%) | (34.82%) | (14.04%) | |
| 14.20% | (9.40%) | (14.56%) | 4.31% | (10.10%) | 10.72% | (6.55%) | (14.70%) | (24.27%) | (10.06%) | |
ROIC |
14.97% | (29.19%) | (21.82%) | 11.65% | 0.00% | 6.31% | (31.42%) | (32.08%) | (32.81%) | (53.44%) |
Return on Tangible Assets |
117.29% | (23.28%) | (25.73%) | 5.29% | (12.88%) | 21.64% | (8.23%) | (21.21%) | (42.30%) | (16.50%) |
Average Days of Receivables |
28.85 | 9.03 | 98.80 | 51.42 | 34.04 | 88.07 | 64.31 | 49.62 | 201.01 | 85.16 |
Research and Development Expense of Revenue |
47.58% | 155.52% | 240.13% | 75.68% | 138.39% | 69.97% | 121.26% | 145.23% | 206.06% | 190.67% |
Selling, General and Administrative Expense of Revenue |
12.02% | 37.92% | 55.35% | 15.50% | 24.20% | 14.12% | 28.85% | 30.57% | 55.40% | 50.68% |
Intangible Assets out of Total Assets |
0.02 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
Share Based Compensation of Revenue |
7.20% | 29.58% | 50.61% | 20.33% | 25.77% | 13.44% | 29.72% | 30.78% | 48.22% | 34.42% |
Graham Net Nets |
0.03 | 0.15 | 0.13 | 0.25 | 0.20 | 0.14 | 0.36 | 0.24 | 0.20 | 0.32 |
Graham Number |
13.67 | 0.00 | 0.00 | 10.76 | 0.00 | 20.04 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
4.34% | (3.44%) | (3.71%) | 1.42% | (2.77%) | 3.54% | (3.55%) | (9.81%) | (15.27%) | (8.10%) |
Free Cash Flow Yield |
8.89% | (3.83%) | (4.56%) | 2.74% | (0.75%) | (1.40%) | (1.22%) | (7.28%) | (14.16%) | (12.25%) |
Revenue per Share |
2.64 | 0.99 | 0.75 | 2.77 | 2.14 | 4.71 | 2.76 | 2.89 | 1.70 | 1.69 |
Operating CF per Share |
2.31 | (0.72) | (1.48) | 1.14 | (0.09) | (0.29) | 0.41 | (1.29) | (3.11) | (1.82) |
Capex per Share |
(0.07) | (0.16) | (0.17) | (0.20) | (0.24) | (0.27) | (0.73) | (0.35) | (0.15) | (0.04) |
Free Cash Flow per Share |
2.23 | (0.87) | (1.65) | 0.94 | (0.33) | (0.56) | (0.32) | (1.64) | (3.25) | (1.86) |
Cash per Share |
3.15 | 4.79 | 5.46 | 9.37 | 10.54 | 5.72 | 10.44 | 9.81 | 7.65 | 7.38 |
Shareholders Equity per Share |
7.61 | 6.76 | 9.67 | 10.49 | 10.01 | 12.56 | 12.20 | 10.94 | 10.36 | 8.56 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.61 | 6.76 | 9.67 | 10.49 | 10.01 | 12.56 | 12.20 | 10.94 | 10.36 | 8.56 |
Free Cash Flow |
92.23 | (40.87) | (88.89) | 53.34 | (18.77) | (32.81) | (18.92) | (99.18) | (211.70) | (138.27) |
Working Capital |
35.37 | 158.23 | 261.87 | 491.85 | 516.61 | 353.63 | 611.50 | 561.69 | 490.17 | 503.91 |
Capital Expenditures |
(3.01) | (7.28) | (9.14) | (11.04) | (13.77) | (15.96) | (43.40) | (21.25) | (9.51) | (3.15) |
Net Current Asset Value |
27.04 | 157.14 | 260.68 | 481.36 | 506.87 | 319.66 | 556.57 | 332.56 | 299.68 | 359.91 |
EV/EBIT |
20.59 | 0.00 | 0.00 | 103.09 | 0.00 | 46.66 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.16 | 0.23 | 0.07 | 0.11 | 0.06 | 0.26 | 0.12 | 0.09 | 0.03 |
Price to Operating Income |
23.55 | 0.00 | 0.00 | 140.63 | 0.00 | 53.52 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.24 | 0.74 | 0.26 | 0.01 | 0.28 | 0.41 | 0.18 | (0.01) | (0.03) | 0.13 |
Cash ROIC |
20.77% | (7.56%) | (10.89%) | 4.70% | (1.58%) | (2.98%) | (1.34%) | (6.86%) | (15.85%) | (10.61%) |
Accounts Receivable Turnover |
25.18 | 9.46 | 6.69 | 9.48 | 7.32 | 7.07 | 3.45 | 6.62 | 2.61 | 2.79 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
4.33 | 4.88 | 6.07 | 16.53 | 16.76 | 38.91 | 47.69 | 26.37 | 42.29 | 45.07 |
Average Payables |
5.14 | 5.37 | 5.33 | 6.99 | 9.57 | 11.48 | 12.04 | 12.00 | 15.34 | 13.79 |
Average Assets |
317.74 | 409.38 | 483.47 | 623.49 | 686.75 | 770.73 | 842.24 | 905.70 | 958.54 | 913.72 |
Average Common Equity |
238.19 | 315.21 | 419.07 | 557.44 | 582.82 | 652.97 | 730.50 | 694.79 | 668.06 | 654.81 |
Columns are period end dates